SidebarExclude – BJC TV https://tv.bjcardio.co.uk Short video updates for cardiologists Wed, 19 Aug 2026 14:16:09 +0000 en-GB hourly 1 https://wordpress.org/?v=7.1.2 https://tv.bjcardio.co.uk/wp-content/uploads/2023/06/cropped-favicon-32x32.png SidebarExclude – BJC TV https://tv.bjcardio.co.uk 32 32 Key differences between Kerendia▼ (finerenone) and steroidal MRAs https://tv.bjcardio.co.uk/cardiovascular-medicine/key-differences-between-kerendia-and-steroidal-mras/ Fri, 19 Jun 2026 14:01:00 +0000 https://tv.bjcardio.co.uk/?p=11756 1–4]]> Prescribing information and adverse event reporting information for Kerendia®▼(finerenone) can be found here.

Featuring

Professor John McMurray, Professor of Cardiology (Cardiology & Metabolic Health), School of Cardiovascular and Metabolic Health
Professor Richard Hobbs, Mercian Professor of Primary Care, University of Oxford

References
  1. Piccirillo F, Liporace P, Nusca A et al. Effects of finerenone on cardiovascular and chronic kidney diseases: a new weapon against cardiorenal morbidity and mortality‑a comprehensive review. J Cardiovasc Dev Dis 2023;10:236.
  2. Kolkhof P, Jaisser F, Kim S-Y et al. Steroidal and novel non‑steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. In Bauersachs J et al (eds): Heart failure. Springer International Publishing, Cham, Switzerland, 2017:271–305.
  3. Spironolactone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/12015/smpc#gref.
  4. Eplerenone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8810/smpc.

DOWNLOAD OUR DOSING GUIDE

]]> The barriers to early diagnosis of cardiac amyloidosis in women https://tv.bjcardio.co.uk/featured-videos-1/the-barriers-to-early-diagnosis-of-cardiac-amyloidosis-in-women/ Tue, 31 Mar 2026 08:18:37 +0000 https://tv.bjcardio.co.uk/?p=11313 Speaker

Professor Marianna Fontana, Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, University College London

For more expert-led non-promotional content on heart failure, cardiac amyloidosis and ATTR-CM, please visit the Pfizer Medical website. Clicking this link will redirect you to the Pfizer Medical website, a non-promotional website developed and funded by Pfizer Ltd. for UK healthcare professionals.

Abbreviation:
ATTR-CM: Transthyretin amyloid cardiomyopathy.

PP-UNP-GBR-14079 | March 2026

]]> British Society of Echocardiography guideline for the TTE assessment of cardiac amyloidosis and the role of ECHO in monitoring disease progression in cardiac amyloidosis https://tv.bjcardio.co.uk/featured-videos-1/british-society-of-echocardiography-guideline-for-the-tte-assessment-of-cardiac-amyloidosis-and-the-role-of-echo-in-monitoring-disease-progression-in-cardiac-amyloidosis/ https://tv.bjcardio.co.uk/featured-videos-1/british-society-of-echocardiography-guideline-for-the-tte-assessment-of-cardiac-amyloidosis-and-the-role-of-echo-in-monitoring-disease-progression-in-cardiac-amyloidosis/#comments Tue, 31 Mar 2026 08:16:57 +0000 https://tv.bjcardio.co.uk/?p=11298 Speaker

Dr William E Moody, Consultant Cardiologist, Queen Elizabeth Hospital, Birmingham

For more expert-led non-promotional content on heart failure, cardiac amyloidosis and transthyretin amyloid cardiomyopathy, please visit the Pfizer Medical website. Clicking this link will redirect you to the Pfizer Medical website, a non-promotional website developed and funded by Pfizer Ltd. for UK healthcare professionals.

Reference

Moody, William E et al. “British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis.” Echo research and practice vol. 10,1 13. 31 Aug. 2023, doi:10.1186/s44156-023-00028-7

Abbreviations:
ECHO: echocardiography; TTE: transthoracic echocardiography.

PP-UNP-GBR-14075 | March 2026

]]> https://tv.bjcardio.co.uk/featured-videos-1/british-society-of-echocardiography-guideline-for-the-tte-assessment-of-cardiac-amyloidosis-and-the-role-of-echo-in-monitoring-disease-progression-in-cardiac-amyloidosis/feed/ 1